These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10857964)

  • 1. Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy.
    Tarnow L; Rossing P; Nielsen FS; Fagerudd JA; Poirier O; Parving HH
    Diabetes Care; 2000 Jan; 23(1):30-3. PubMed ID: 10857964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy.
    Tarnow L; Cambien F; Rossing P; Nielsen FS; Hansen BV; Lecerf L; Poirier O; Danilov S; Boelskifte S; Borch-Johnsen K
    Diabetologia; 1995 Jul; 38(7):798-803. PubMed ID: 7556981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of familial predisposition to cardiovascular disease in type 1 (insulin-dependent) diabetic patients with nephropathy.
    Nørgaard K; Mathiesen ER; Hommel E; Jensen JS; Parving HH
    Diabetologia; 1991 May; 34(5):370-2. PubMed ID: 1864492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy.
    Tarnow L; Rossing P; Nielsen FS; Hansen BV; Dyerberg J; Parving HH
    Diabetes Care; 1996 Dec; 19(12):1382-7. PubMed ID: 8941468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes.
    Tarnow L; Hovind P; Teerlink T; Stehouwer CD; Parving HH
    Diabetes Care; 2004 Mar; 27(3):765-9. PubMed ID: 14988299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
    Lajer M; Tarnow I; Michelson AD; Jorsal A; Frelinger AL; Parving HH; Rossing P; Tarnow L
    Platelets; 2010; 21(7):525-32. PubMed ID: 20701458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
    Lajer M; Tarnow L; Jorsal A; Teerlink T; Parving HH; Rossing P
    Diabetes Care; 2008 Apr; 31(4):747-52. PubMed ID: 18162497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clustering of risk factors in parents of patients with type 1 diabetes and nephropathy.
    Thorn LM; Forsblom C; Fagerudd J; Pettersson-Fernholm K; Kilpikari R; Groop PH;
    Diabetes Care; 2007 May; 30(5):1162-7. PubMed ID: 17337502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy.
    Earle K; Walker J; Hill C; Viberti G
    N Engl J Med; 1992 Mar; 326(10):673-7. PubMed ID: 1736105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
    Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease.
    Fragoso A; Mendes F; Silva AP; Neves PL
    J Diabetes Complications; 2015; 29(8):1098-104. PubMed ID: 26066409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria.
    De Cosmo S; Bacci S; Piras GP; Cignarelli M; Placentino G; Margaglione M; Colaizzo D; Di Minno G; Giorgino R; Liuzzi A; Viberti GC
    Diabetologia; 1997 Oct; 40(10):1191-6. PubMed ID: 9349601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.
    Lajer M; Jorsal A; Tarnow L; Parving HH; Rossing P
    Diabetes Care; 2010 Jul; 33(7):1567-72. PubMed ID: 20357380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
    Astrup AS; Tarnow L; Rossing P; Hansen BV; Hilsted J; Parving HH
    Diabetes Care; 2006 Feb; 29(2):334-9. PubMed ID: 16443883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy.
    Sato A; Tarnow L; Parving HH
    Diabetologia; 1999 Jan; 42(1):76-80. PubMed ID: 10027582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated placental growth factor (PlGF) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.
    Tarnow L; Astrup AS; Parving HH
    Scand J Clin Lab Invest Suppl; 2005; 240():73-9. PubMed ID: 16112962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland.
    Tuomilehto J; Borch-Johnsen K; Molarius A; Forsén T; Rastenyte D; Sarti C; Reunanen A
    Diabetologia; 1998 Jul; 41(7):784-90. PubMed ID: 9686919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy.
    Tarnow L; Hildebrandt P; Hansen BV; Borch-Johnsen K; Parving HH
    Diabetologia; 2005 Jan; 48(1):149-55. PubMed ID: 15616804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes.
    Thorn LM; Forsblom C; Wadén J; Saraheimo M; Tolonen N; Hietala K; Groop PH;
    Diabetes Care; 2009 May; 32(5):950-2. PubMed ID: 19196885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes.
    Möllsten A; Jorsal A; Lajer M; Vionnet N; Tarnow L
    Diabetologia; 2009 Dec; 52(12):2590-3. PubMed ID: 19834686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.